Table 1.

Effect of statins on CRP levels in clinical trials

(Ref.)	Drug	Time of intervention	Median baseline CRP level (mg·L−1)	CRP % change (P value)
(Ridker et al., 1999)	Pravastatin	5 years	2.3	−17.4 (P = 0.004)
(Ridker et al., 2001)	Lovastatin	1 year	1.6	−14.8 (P < 0.001)
(Albert et al., 2001)	Pravastatin	24 weeks	2.0	−14.2 (P < 0.001)
(Jialal et al., 2001)	Pravastatin	6 weeks	2.6	−20.3 (P < 0.025)
	Simvastatin			−22.8 (P < 0.025)
	Atorvastatin			−28.3 (P < 0.025)
(Kinlay et al., 2003)	Atorvastatin	16 weeks	11.5	−34 (P < 0.0001)
(Nissen et al., 2004)	Pravastatin	18 months	3.0	−5.2
	Atorvastatin			−36.4 (P < 0.001 vs. pravastatin)
(Ridker et al., 2005)	Atorvastatin	24 months	12.2	−89.3 (P < 0.001)
	Pravastatin		11.9	−82.4 (P < 0.001)
(Morrow et al., 2006)	Simvastatin	4 months	2.4	−29.2 (P < 0.0001)
(Ridker et al., 2008)	Rosuvastatin	48 months	4.2	−57.1 (P < 0.001)
(Emberson et al., 2011)	Simvastatin	5.0 years	3.07	−27 (P < 0.0001)
(Sever et al., 2013)	Atorvastatin	6 months	2.4 w/o events 3.0 w/ events	−25.8 (P < 0.02)
(Soedamah‐Muthu et al., 2015)	Atorvastatin	1 year	1.3	−9.8